President Donald Trump has signed a sweeping executive order aimed at dramatically reducing prescription drug prices for Americans by tying them to the significantly lower rates paid in other developed countries.
The bold move represents the administration’s latest attempt to tackle one of the most pressing healthcare concerns for many Americans — the high cost of medications.
The ‘most favored nation’ approach returns
The executive order revives Trump’s controversial “most favored nation” policy, which seeks to ensure Americans pay no more for medications than consumers in other developed nations.
Currently, Americans pay two to three times more for prescription drugs than people in other developed countries, and up to 10 times more than in certain nations.
At Monday’s press event announcing the executive order, Trump said the goal is to “equalize” pricing, stating, “We are going to pay the lowest price there is in the world.”
The president claimed the policy could reduce drug prices by 59% to 90%, though analysts question whether such reductions are achievable.
Lower drug prices are the goal, but everyday savings start with smarter choices. If you’re spending more than $15 a month on cell service, click here to save a bundle.
How the order aims to lower costs
The executive order contains several key provisions designed to address high drug prices:
- It directs the Department of Health and Human Services (HHS) to establish a pathway for American patients to purchase medications directly from manufacturers at “most favored nation” prices, bypassing middlemen.
- Within 30 days, the HHS Secretary must set clear targets for price reductions across all U.S. markets.
- If “adequate progress” isn’t made toward those targets, HHS Secretary Robert F. Kennedy Jr. is directed to implement most-favored-nation pricing by creating new federal regulations.
- The FDA will consider expanding imports beyond Canada to include other developed nations.
- The Department of Justice and the Federal Trade Commission will aggressively enforce actions against anti-competitive behaviors that keep prices high.
Pushing back against foreign price controls
The order also takes aim at foreign countries that negotiate lower drug prices, arguing they aren’t paying their fair share for pharmaceutical innovation.
Trump stated that the U.S. would “no longer subsidize the health care of foreign countries,” referring to the disparity in global drug pricing.
The executive order instructs the U.S. Trade Representative and Department of Commerce to crack down on what it describes as “unreasonable and discriminatory policies” in other countries that “suppress” drug prices abroad.
Drug prices may change, but making the most of your healthcare coverage is still essential. Need Medicare help? Maximize benefits & save money. Get unbiased guidance. Compare plans today.
Industry and advocacy reactions
The pharmaceutical industry’s largest lobbying group, the Pharmaceutical Research and Manufacturers of America (PhRMA), immediately opposed the policy.
CEO Stephen Ubl said, “Importing foreign prices from socialist countries would be a bad deal for American patients and workers” because it could impact the industry’s ability to develop new treatments.
On the other side of the debate, AARP, applauded the order.
“For too long, big drug companies have been ripping off America’s seniors—charging the highest prices in the world for lifesaving prescriptions,” said Nancy LeaMond, AARP’s chief advocacy and engagement officer.
Significant implementation challenges ahead
While the executive order outlines an ambitious approach to lowering drug costs, its path to implementation remains uncertain. JPMorgan analysts called the policy “challenging to practically implement” because it would likely require congressional approval and could face legal hurdles.
This isn’t the first attempt at such a policy. The pharmaceutical industry successfully blocked a similar Trump administration effort during his first term through legal action. After a federal judge halted that policy following industry lawsuits, the Biden administration rescinded it.
Given the complex global pharmaceutical market dynamics, some health policy experts have also questioned whether such a policy can effectively lower medication costs.
Prescription prices aren’t the only out-of-pocket cost to watch. If you’re on a high-deductible plan, you should have a Health Savings Account. Check out Lively HSAs.
Despite these obstacles, the administration appears determined to move forward with this significant effort to address one of the most persistent healthcare affordability issues facing American consumers.
Add a Comment